BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 2319512)

  • 1. Development of beta-lactamase inhibitors.
    Sutherland R
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Surg Gynecol Obstet; 1991; 172 Suppl():11-6. PubMed ID: 2024221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of beta-lactamase inhibitors.
    Jackson D
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ticarcillin and ticarcillin/clavulanic acid on the in-vitro activity of human granulocytes against beta-lactamase-producing Klebsiella pneumoniae.
    Cuffini AM; de Renzi G; Tullio V; Paizis G; Carlone NA
    Int J Tissue React; 1995; 17(5-6):199-203. PubMed ID: 8835630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
    Moittie D; Simonet M; Veron M
    Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
    Sanders CV; Aldridge KE
    J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
    Hardin TC; Butler SC; Ross S; Wakeford JH; Jorgensen JH
    Pharmacotherapy; 1994; 14(2):147-52. PubMed ID: 8197032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-lactamase inhibitors from laboratory to clinic.
    Bush K
    Clin Microbiol Rev; 1988 Jan; 1(1):109-23. PubMed ID: 3060240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases.
    Grace ME; Fu KP; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(3):145-8. PubMed ID: 3040368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ampicillin-sulbactam and ticarcillin-clavulanic acid: a comparison of their in vitro activity and review of their clinical efficacy.
    Itokazu GS; Danziger LH
    Pharmacotherapy; 1991; 11(5):382-414. PubMed ID: 1745624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming enzymatic resistance in bacteria: impact on future therapy.
    Labia R; Barthélémy M; Péduzzi J; Morand A; Tiwari K; Kazmierczak A
    J Int Med Res; 1990; 18 Suppl 4():48D-57D. PubMed ID: 2282969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors.
    Maddux MS
    Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of human polymorphonuclear leukocyte phagocytosis and intracellular bactericidal activity by amoxycillin/clavulanic acid.
    Cuffini AM; De Renzi G; Tullio V; Paizis G; Carlone NA
    Drugs Exp Clin Res; 1996; 22(1):9-15. PubMed ID: 8839632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    J Reprod Med; 1988 Jun; 33(6 Suppl):571-3. PubMed ID: 3294401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.
    Venkatesan AM; Agarwal A; Abe T; Ushirogochi H; Yamamura I; Kumagai T; Petersen PJ; Weiss WJ; Lenoy E; Yang Y; Shlaes DM; Ryan JL; Mansour TS
    Bioorg Med Chem; 2004 Nov; 12(22):5807-17. PubMed ID: 15498657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.